Chris O’Brien

754 total citations
32 papers, 557 citations indexed

About

Chris O’Brien is a scholar working on Genetics, Epidemiology and Reproductive Medicine. According to data from OpenAlex, Chris O’Brien has authored 32 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 6 papers in Epidemiology and 6 papers in Reproductive Medicine. Recurrent topics in Chris O’Brien's work include Inflammatory Bowel Disease (10 papers), Endometriosis Research and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Chris O’Brien is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Endometriosis Research and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Chris O’Brien collaborates with scholars based in United States, Australia and United Kingdom. Chris O’Brien's co-authors include Joshua Burke, Roland Jimenez, Kristof Chwalisż, Ping Jiang, Bruce R. Carr, W. Paul Dmowski, Elizabeth Garner, Mark Mahowald, Conrad Iber and Scott Davies and has published in prestigious journals such as PEDIATRICS, SLEEP and Fertility and Sterility.

In The Last Decade

Chris O’Brien

31 papers receiving 538 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris O’Brien United States	13	161	140	120	90	79	32	557
Katharina Hancke Germany	14	240 1.5×	119 0.8×	32 0.3×	97 1.1×	91 1.2×	48	807
Sa Jin Kim South Korea	13	31 0.2×	153 1.1×	27 0.2×	39 0.4×	51 0.6×	60	483
Marı́a del Carmen Cravioto Mexico	18	260 1.6×	73 0.5×	74 0.6×	292 3.2×	22 0.3×	37	1.0k
Peter Könings Sweden	17	94 0.6×	43 0.3×	462 3.9×	81 0.9×	39 0.5×	33	1.3k
Haller J. Smith United States	17	108 0.7×	72 0.5×	31 0.3×	126 1.4×	95 1.2×	61	869
Slavko Orešković Croatia	16	189 1.2×	117 0.8×	38 0.3×	23 0.3×	51 0.6×	60	674
Amy L. Gross United States	10	289 1.8×	152 1.1×	68 0.6×	29 0.3×	59 0.7×	14	538
Tim Mould United Kingdom	17	398 2.5×	483 3.5×	88 0.7×	40 0.4×	167 2.1×	48	980
Sigi Rotmensch Israel	11	60 0.4×	212 1.5×	14 0.1×	27 0.3×	34 0.4×	23	487
Katsuhiko Naruse Japan	18	126 0.8×	882 6.3×	23 0.2×	445 4.9×	158 2.0×	72	1.3k

Countries citing papers authored by Chris O’Brien

Since Specialization

Citations

This map shows the geographic impact of Chris O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris O’Brien more than expected).

Fields of papers citing papers by Chris O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris O’Brien. The network helps show where Chris O’Brien may publish in the future.

Co-authorship network of co-authors of Chris O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Chris O’Brien. A scholar is included among the top collaborators of Chris O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris O’Brien. Chris O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tucker, Matthew S., Chris O’Brien, Manan Sharma, et al.. (2024). Filters comprised of sand and Zero Valent Iron hold promise as tools to mitigate risk posed by Cyclospora cayetanensis oocysts. Food and Waterborne Parasitology. 37. e00243–e00243. 1 indexed citations

Danese, Silvio, Remo Panaccione, Laurent Peyrin‐Biroulet, et al.. (2020). P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension. Journal of Crohn s and Colitis. 14(Supplement_1). S403–S403. 3 indexed citations

Sands, B E, María T. Abreu, Rupert W. Leong, et al.. (2020). P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension. Journal of Crohn s and Colitis. 14(Supplement_1). S476–S477. 2 indexed citations

Rosh, Joel R., Dan Turner, Anne M. Griffiths, et al.. (2020). DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study. Journal of Crohn s and Colitis. 14(Supplement_1). S107–S108. 1 indexed citations

Adedokun, Omoniyi J., Zhenhua Xu, Colleen Marano, et al.. (2019). Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 18(10). 2244–2255.e9. 77 indexed citations

Adedokun, Omoniyi J., Zhenhua Xu, Colleen Marano, et al.. (2019). P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study. Journal of Crohn s and Colitis. 13(Supplement_1). S255–S256.

Dautovich, Natalie D., et al.. (2018). A systematic review of the amount and timing of light in association with objective and subjective sleep outcomes in community-dwelling adults. Sleep Health. 5(1). 31–48. 30 indexed citations

Kelly, John R., Yuliya Borre, Chris O’Brien, et al.. (2016). Towards an understanding of depression-associated gut microbiota induced neurobehavioural changes in the rat. European Neuropsychopharmacology. 26. S416–S417. 2 indexed citations

Graham, Simon, Rebecca Guy, James Ward, et al.. (2015). Incidence and predictors of annual chlamydia testing among 15–29 year olds attending Aboriginal primary health care services in New South Wales, Australia. BMC Health Services Research. 15(1). 437–437. 2 indexed citations

10.

Graham, Simon, Rebecca Guy, Handan Wand, et al.. (2015). A sexual health quality improvement program (SHIMMER) triples chlamydia and gonorrhoea testing rates among young people attending Aboriginal primary health care services in Australia. BMC Infectious Diseases. 15(1). 370–370. 13 indexed citations

11.

Ács, Nándor, Chris O’Brien, Ping Jiang, et al.. (2015). Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study. Journal of Endometriosis and Pelvic Pain Disorders. 7(2). 56–62. 25 indexed citations

12.

Graham, Simon, Handan Wand, James Ward, et al.. (2015). Attendance patterns and chlamydia and gonorrhoea testing among young people in Aboriginal primary health centres in New South Wales, Australia. Sexual Health. 12(5). 445–452. 6 indexed citations

13.

Genovese, Mark C., et al.. (2014). A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist. The Journal of Rheumatology. 41(11). 2120–2128. 55 indexed citations

14.

Carr, Bruce R., W. Paul Dmowski, Chris O’Brien, et al.. (2014). Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density. Reproductive Sciences. 21(11). 1341–1351. 80 indexed citations

15.

Dawes, Patrick, Aleksandar Dimić, Mark C. Genovese, et al.. (2013). Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. Data Archiving and Networked Services (DANS). 65. 13 indexed citations

16.

Imani, Reza, et al.. (2009). Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis. Fertility and Sterility. 92(3). S111–S112. 6 indexed citations

17.

Madan, Ajay, Zhihong O’Brien, Chris O’Brien, et al.. (2009). A pharmacokinetic evaluation of five H₁ antagonists after an oral and intravenous microdose to human subjects. British Journal of Clinical Pharmacology. 67(3). 288–298. 40 indexed citations

18.

O’Brien, Chris, et al.. (2005). How long do people expect to live? Results and implications. 17 indexed citations

19.

Conacher, I.D., D. Meikle, & Chris O’Brien. (2002). Tracheostomy, lingular tonsillectomy and sleep-related breathing disorders. British Journal of Anaesthesia. 88(5). 724–726. 11 indexed citations

20.

Heil, Gerhard, Miguel Á. Sanz, Klaus Lechner, et al.. (1995). Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Ghent University Academic Bibliography (Ghent University). 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact